Clopidogrel Bisulfate
Product Images NDC 71335-1232

11 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 71335-1232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

4ec4203e F1f8 0398 E054 00144ff88e88

4ec4203e F1f8 0398 E054 00144ff88e88
Clopidogrel bisulfate round pink tablets with imprint 'SG' on one side and '124' on the other side. Manufactured by Bryant Ranch Prepack. No strength or package size is visible in the image.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A horizontal error bar chart showing the effect of co-administered proton pump inhibitors (PPIs) on exposure to clopidogrel active metabolite AUC after multiple doses of 75 mg clopidogrel. The chart lists four PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the y-axis and shows their mean effect with 90% confidence intervals relative to clopidogrel administered alone on the x-axis, ranging from 0.4 to 1.4.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph titled 'Cardiovascular Death, Myocardial Infarction, Stroke' showing cumulative event rate (%) on the y-axis versus months of follow up on the x-axis up to 12 months. It compares event rates between placebo (+ aspirin) and clopidogrel (+ aspirin) groups. The placebo group shows a higher cumulative event rate than the clopidogrel group over time. A p-value of 0.00009 is noted, indicating statistical significance. A footnote mentions other standard therapies were used as appropriate.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A hazard ratio forest plot chart illustrating patient baseline characteristics and concomitant medications/interventions for the CURE Study with Clopidogrel bisulfate. The chart compares subgroups by age, gender, race, enzyme elevation, diabetes, previous MI/stroke, and various medications, showing the number of patients, event counts, and confidence intervals favoring Clopidogrel or placebo.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A survival curve chart comparing percent dead before first discharge for Clopidogrel bisulfate versus placebo over 28 days since randomization. The graph shows slightly lower deaths with Clopidogrel (7.5%) compared to placebo (8.1%), representing a 7% proportional risk reduction (p=0.03).*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier curve showing the percentage of subjects with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares two groups: placebo with 10.1% event rate and clopidogrel with 9.2% event rate, indicating a 9% proportional risk reduction with clopidogrel (p=0.002).*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A forest plot displaying odds ratios with 99% confidence intervals comparing Clopidogrel versus placebo across subgroups based on gender, age, time since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent use. It includes the number of subjects (N), and event counts with percentages for Clopidogrel and placebo groups, concluding with an overall odds ratio. The plot shows which subgroups favor Clopidogrel or placebo.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A line graph comparing the cumulative event rate (%) of fatal or non-fatal vascular events over months of follow-up for aspirin and clopidogrel. The graph shows two lines gradually increasing over a 36-month period, with clopidogrel generally showing a lower event rate than aspirin. A statistical significance is indicated by P=0.045.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A forest plot displaying the hazard ratios with 95% confidence intervals for Clopidogrel versus Aspirin across four qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral artery disease), and Overall. The chart compares event percentages for Clopidogrel and Aspirin groups, illustrating if the data favors Clopidogrel or Aspirin along a horizontal hazard ratio axis ranging from 0.6 to 1.3.*
FDA Label Image

Structural Formula (Structural Formula)

Structural Formula (Structural Formula)
Chemical structure depicting the active ingredient clopidogrel bisulfate, showing its molecular components including a thiophene ring, a chlorophenyl group, and an acetate ester, along with the sulfate component represented as H2SO4.*
FDA Label Image

Label Image (Lbl713351232)

Label Image (Lbl713351232)
Clopidogrel bisulfate 75mg tablet label packed by Bryant Ranch Prepack, Burbank, CA. The label compares it to Plavix 75mg tablets from ScieGen Pharmaceuticals Inc. It indicates a package size of 90 tablets with storage instructions to keep in a light-resistant container at 20°-25°C (68°-77°F). The NDC is 71335-1232.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.